A novel cell-based sensor detecting the activity of individual basic proprotein convertases

The basic proprotein convertases (PCs) furin, PC1/3, PC2, PC5/6, PACE4, PC4, and PC7 are promising drug targets for human diseases. However, developing selective inhibitors remains challenging due to overlapping substrate recognition motifs and limited structural information. Classical drug screening approaches for basic PC inhibitors involve homogeneous biochemical assays using soluble recombinant enzymes combined with fluorogenic substrate peptides and do not accurately recapitulate the complex cellular context of the basic PC-substrate interaction. We report here PCific, a novel cell-based molecular sensor that allows rapid screening of candidate inhibitors and their selectivity toward individual basic PCs within mammalian cells. PCific consists of Gaussia luciferase linked to a sortilin-1 membrane anchor via a cleavage motif that allows efficient release of luciferase specifically if individual basic PCs are provided in cis. Screening of selected candidate peptidomimetic inhibitors revealed that PCific can readily distinguish between general and selective PC inhibitors in a high-throughput screening format.

[1]  Kornelia Hardes,et al.  New substrate analogue furin inhibitors derived from 4-amidinobenzylamide. , 2011, Bioorganic & medicinal chemistry letters.

[2]  M. Vey,et al.  Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin‐like endoprotease. , 1992, The EMBO journal.

[3]  T. Willnow,et al.  VPS10P-domain receptors — regulators of neuronal viability and function , 2008, Nature Reviews Neuroscience.

[4]  D. Constam,et al.  Imaging proprotein convertase activities and their regulation in the implanting mouse blastocyst , 2010, The Journal of cell biology.

[5]  A. Amon,et al.  Emerging roles for centromeres in meiosis I chromosome segregation , 2008, Nature Reviews Genetics.

[6]  N. Seidah,et al.  Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides 1 Published on the World Wide Web on 17 August 1999. 1 , 1999, Brain Research.

[7]  I. Lindberg,et al.  Optimization of Substrate‐Analogue Furin Inhibitors , 2017, ChemMedChem.

[8]  M. Than,et al.  Structural Studies Revealed Active Site Distortions of Human Furin by a Small Molecule Inhibitor. , 2017, ACS chemical biology.

[9]  I. Lindberg,et al.  Highly Potent Inhibitors of Proprotein Convertase Furin as Potential Drugs for Treatment of Infectious Diseases* , 2012, The Journal of Biological Chemistry.

[10]  N. Seidah,et al.  Proprotein Convertase Activity Contributes to the Processing of the Alzheimer's β‐Amyloid Precursor Protein in Human Cells: Evidence for a Role of the Prohormone Convertase PC7 in the Constitutive ‐Secretase Pathway , 1999, Journal of neurochemistry.

[11]  S. Kunz,et al.  A Molecular Sensor To Characterize Arenavirus Envelope Glycoprotein Cleavage by Subtilisin Kexin Isozyme 1/Site 1 Protease , 2015, Journal of Virology.

[12]  G. Thomas,et al.  Furin at the cutting edge: From protein traffic to embryogenesis and disease , 2002, Nature Reviews Molecular Cell Biology.

[13]  P. Jaaks,et al.  The proprotein convertase furin in tumour progression , 2017, International journal of cancer.

[14]  S. Brunak,et al.  A Systematic Study of Site-specific GalNAc-type O-Glycosylation Modulating Proprotein Convertase Processing* , 2011, The Journal of Biological Chemistry.

[15]  N. Seidah The proprotein convertases, 20 years later. , 2011, Methods in molecular biology.

[16]  M. Mumby,et al.  Regulation of Endosome Sorting by a Specific PP2A Isoform , 1998, The Journal of cell biology.

[17]  N. Seidah,et al.  Mechanism of Folding and Activation of Subtilisin Kexin Isozyme-1 (SKI-1)/Site-1 Protease (S1P)* , 2015, The Journal of Biological Chemistry.

[18]  S. Opal,et al.  Proprotein convertases in health and disease. , 2011, The New England journal of medicine.

[19]  K. Nakayama,et al.  Localization of Furin to the trans-Golgi Network and Recycling from the Cell Surface Involves Ser and Tyr Residues within the Cytoplasmic Domain (*) , 1995, The Journal of Biological Chemistry.

[20]  P. Gleeson,et al.  Rab9-dependent retrograde transport and endosomal sorting of the endopeptidase furin , 2011, Journal of Cell Science.

[21]  G. Thomas,et al.  The Ordered and Compartment-specific Autoproteolytic Removal of the Furin Intramolecular Chaperone Is Required for Enzyme Activation* , 2002, The Journal of Biological Chemistry.

[22]  D. Constam,et al.  PC7 and the related proteases Furin and Pace4 regulate E-cadherin function during blastocyst formation , 2015, The Journal of cell biology.

[23]  F. Maxfield,et al.  Chimeric Forms of Furin and Tgn38 Are Transported from the Plasma Membrane to the Trans-Golgi Network via Distinct Endosomal Pathways , 1999, The Journal of cell biology.

[24]  I. Lindberg,et al.  Identification of Inhibitors of Prohormone Convertases 1 and 2 Using a Peptide Combinatorial Library* , 1998, The Journal of Biological Chemistry.

[25]  A. Beaudet,et al.  Internalization and trafficking of neurotensin via NTS3 receptors in HT29 cells. , 2004, The international journal of biochemistry & cell biology.

[26]  L. Wan,et al.  PACS-1 Defines a Novel Gene Family of Cytosolic Sorting Proteins Required for trans-Golgi Network Localization , 1998, Cell.

[27]  R. Day,et al.  Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition , 2005, Trends in Pharmacological Sciences.

[28]  B. Ross,et al.  Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. , 2007, Analytical biochemistry.

[29]  I. Lindberg,et al.  Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. , 2010, Journal of medicinal chemistry.

[30]  A. Linstedt,et al.  A Sensor of Protein O‐Glycosylation Based on Sequential Processing in the Golgi Apparatus , 2013, Traffic.

[31]  D. Constam,et al.  Compartment-Specific Biosensors Reveal a Complementary Subcellular Distribution of Bioactive Furin and PC7. , 2018, Cell reports.

[32]  D. Constam,et al.  The microenvironment patterns the pluripotent mouse epiblast through paracrine Furin and Pace4 proteolytic activities. , 2011, Genes & development.

[33]  Annik Prat,et al.  The biology and therapeutic targeting of the proprotein convertases , 2012, Nature Reviews Drug Discovery.

[34]  I. Lindberg,et al.  Polyarginines Are Potent Furin Inhibitors* , 2000, The Journal of Biological Chemistry.

[35]  R. Huber,et al.  Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism , 2016, Proceedings of the National Academy of Sciences.

[36]  R. Day,et al.  Therapeutic uses of furin and its inhibitors: a patent review , 2015, Expert opinion on therapeutic patents.

[37]  B. Grant,et al.  Intracellular trafficking. , 2006, WormBook : the online review of C. elegans biology.

[38]  Huiyu Jiang,et al.  Inhibition of furin results in increased growth, invasiveness and cytokine production of synoviocytes from patients with rheumatoid arthritis. , 2017, Joint, bone, spine : revue du rhumatisme.

[39]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[40]  A. Prat,et al.  The proprotein convertases are potential targets in the treatment of dyslipidemia , 2007, Journal of Molecular Medicine.

[41]  Y. Loh,et al.  60 YEARS OF POMC: Biosynthesis, trafficking, and secretion of pro-opiomelanocortin-derived peptides. , 2016, Journal of molecular endocrinology.

[42]  A. Prat,et al.  Precursor convertases in the secretory pathway, cytosol and extracellular milieu. , 2002, Essays in biochemistry.

[43]  H. Klenk,et al.  Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gpl60 , 1992, Nature.

[44]  T. Komiyama,et al.  Engineered eglin c variants inhibit yeast and human proprotein processing proteases, Kex2 and furin. , 2000, Biochemistry.

[45]  H. Klenk,et al.  Endoproteolytic Cleavage of Its Propeptide Is a Prerequisite for Efficient Transport of Furin Out of the Endoplasmic Reticulum (*) , 1995, The Journal of Biological Chemistry.

[46]  I. Lindberg,et al.  Novel Furin Inhibitors with Potent Anti‐infectious Activity , 2015, ChemMedChem.

[47]  D. Teplow,et al.  A Furin-like Convertase Mediates Propeptide Cleavage of BACE, the Alzheimer's β-Secretase* , 2000, The Journal of Biological Chemistry.

[48]  N. Seidah,et al.  Zymogen Activation and Subcellular Activity of Subtilisin Kexin Isozyme 1/Site 1 Protease* , 2014, The Journal of Biological Chemistry.

[49]  H. Brandstetter,et al.  X-ray Structures of Human Furin in Complex with Competitive Inhibitors , 2014, ACS chemical biology.

[50]  G. Thomas,et al.  Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. , 1994, The EMBO journal.

[51]  S. Millis,et al.  Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine , 2006, Proceedings of the National Academy of Sciences.

[52]  E. Fleck,et al.  Proprotein convertases furin and PC5: targeting atherosclerosis and restenosis at multiple levels , 2005, Journal of Molecular Medicine.

[53]  N. Seidah,et al.  Mammalian subtilisin/kexin isozyme SKI-1: A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Prat,et al.  The activation and physiological functions of the proprotein convertases. , 2008, The international journal of biochemistry & cell biology.